Vitiligo Therapeutics - Pipeline Assessment and Market Forecasts to 2019

NEW YORK, Feb. 7, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0769442/Vitiligo-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Vitiligo Therapeutics - Pipeline Assessment and Market Forecasts to 2019

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Vitiligo Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Vitiligo Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Vitiligo Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Vitiligo Therapeutics market

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Vitiligo Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Vitiligo Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Vitiligo Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Vitiligo Therapeutics - Introduction 72.1 Disease Overview 72.2 Epidemiology 92.3 Etiology and Pathophysiology 92.3.1 Etiology of Vitiligo 92.3.2 Pathophysiology of Vitiligo 92.4 Signs and Symptoms 102.5 Diagnosis 112.6 Treatment and Management Options 112.6.1 Medical Therapies 112.6.2 Surgical Therapies 122.6.3 Additional Therapies 132.7 GlobalData Pipeline Report Guidance 143 Vitiligo Therapeutics - Market Characterization 153.1 Vitiligo Therapeutics Market Size (2006-2011) - Global 153.2 Vitiligo Therapeutics Market Forecast (2011-2019) - Global 173.3 Vitiligo Therapeutics Market Size (2006-2011) - The US 183.4 Vitiligo Therapeutics Market Forecast (2011-2019) - The US 193.5 Vitiligo Therapeutics Market Size (2006-2011) - France 203.6 Vitiligo Therapeutics Market Forecast (2011-2019) - France 213.7 Vitiligo Therapeutics Market Size (2006-2011) - Germany 223.8 Vitiligo Therapeutics Market Forecast (2011-2019) - Germany 233.9 Vitiligo Therapeutics Market Size (2006-2011) - Italy 243.10 Vitiligo Therapeutics Market Forecast (2011-2019) - Italy 253.11 Vitiligo Therapeutics Market Size (2006-2011) - Spain 263.12 Vitiligo Therapeutics Market Forecast (2011-2019) - Spain 273.13 Vitiligo Therapeutics Market Size (2006-2011) - The UK 283.14 Vitiligo Therapeutics Market Forecast (2011-2019) - The UK 293.15 Vitiligo Therapeutics Market Size (2006-2011) - Japan 303.16 Vitiligo Therapeutics Market Forecast (2011-2019) - Japan 313.17 Drivers and Barriers for the Vitiligo Therapeutics Market 323.17.1 Drivers for the Vitiligo Therapeutics Market 323.17.2 Barriers for the Vitiligo Therapeutics Market 323.18 Opportunity and Unmet Need 333.19 Key Takeaway 344 Vitiligo Therapeutics - Competitive Assessment 354.1 Overview 354.2 Strategic Competitor Assessment 354.3 Product Profile for the Major Marketed Products in the Vitiligo Therapeutics Market 364.3.1 Topical Corticosteroids 364.3.2 Topical Immunomodulators 374.3.3 Methoxsalen 394.4 Key Takeaway 395 Vitiligo Therapeutics - Pipeline Assessment 405.1 Overview 405.2 Strategic Pipeline Assessment 405.3 Vitiligo Therapeutics - Pipeline Analysis by Clinical Phase of Development 405.3.1 Vitiligo Therapeutics - Phase III Clinical Pipeline 415.3.2 Vitiligo Therapeutics - Phase II Clinical Pipeline 415.3.3 Vitiligo Therapeutics - Preclinical Phase Pipeline 415.4 Vitiligo Therapeutics - Pipeline by Mechanism of Action 425.5 Technology Trends Analytical Framework 435.6 Vitiligo Therapeutics - Most Promising Drugs in Clinical Development 445.7 Most Promising Drug Profiles 445.7.1 Scenesse (afamelanotide) 445.8 Key Takeaway 456 Vitiligo Therapeutics - Clinical Trials Mapping 466.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 466.2 Clinical Trials by Phase of Clinical Development 476.3 Clinical Trials by Trial Status 486.4 Prominent Sponsors 496.5 Clinical Trials by Sponsors 506.6 Top Companies Participating in Vitiligo Therapeutics Clinical Trials 507 Vitiligo Therapeutics - Strategic Assessment 517.1 Key Events Impacting the Future Market 517.2 Future Market Competition Scenario 528 Vitiligo Therapeutics - Future Players 538.1 Introduction 538.2 Company Profiles 548.2.1 Clinuvel Pharmaceuticals 548.2.2 Switch Biotech 558.2.3 Dermira 558.3 Key Takeaway 569 Vitiligo Therapeutics - Licensing & Partnership Deals 5710 Vitiligo Therapeutics - Appendix 5810.1 Definitions 5810.2 Acronyms 5810.3 Research Methodology 5810.3.1 Coverage 5910.3.2 Secondary Research 5910.3.3 Forecasting 5910.3.4 Primary Research 6110.3.5 Expert Panel Validation 6210.4 Contact Us 6210.5 Disclaimer 6210.6 Bibliography 63

List of Tables

Table 1: Characteristics of Various Types of Vitiligo 7Table 2: Vitiligo Prevalence in Seven Major Markets 9Table 3: Vitiligo Therapeutics Market, Global, Revenue ($m), 2006-2011 16Table 4: Vitiligo Therapeutics Market, Global, Forecast ($m), 2011-2019 17Table 5: Vitiligo Therapeutics Market, The US, Revenue ($m), 2006-2011 18Table 6: Vitiligo Therapeutics Market, The US, Forecast ($m), 2011-2019 19Table 7: Vitiligo Therapeutics Market, France, Revenue ($m), 2006-2011 20Table 8: Vitiligo Therapeutics Market, France, Forecast ($m), 2011-2019 21Table 9: Vitiligo Therapeutics Market, Germany, Revenue ($m), 2006-2011 22Table 10: Vitiligo Therapeutics Market, Germany, Forecast ($m), 2011-2019 23Table 11: Vitiligo Therapeutics Market, Italy, Revenue ($m), 2006-2011 24Table 12: Vitiligo Therapeutics Market, Italy, Forecast ($m), 2011-2019 25Table 13: Vitiligo Therapeutics Market, Spain, Revenue ($m), 2006-2011 26Table 14: Vitiligo Therapeutics Market, Spain, Forecast ($m), 2011-2019 27Table 15: Vitiligo Therapeutics Market, The UK, Revenue ($m), 2006-2011 28Table 16: Vitiligo Therapeutics Market, The UK, Forecast ($m), 2011-2019 29Table 17: Vitiligo Therapeutics Market, Japan, Revenue ($m), 2006-2011 30Table 18: Vitiligo Therapeutics Market, Japan, Forecast ($m), 2011-2019 31Table 19: Vitiligo Therapeutics Market, Phase III Pipeline, 2011 41Table 20: Vitiligo Therapeutics Market, Phase II Pipeline, 2011 41Table 21: Vitiligo Therapeutics Market, Pre-clinical and Discovery Phase Pipeline, 2011 41Table 22: Vitiligo Therapeutics Market, Global, Most Promising Drugs in Clinical Development, 2011 44Table 23: Vitiligo Therapeutics, Global, Clinical Trials, 2011 46Table 24: Vitiligo Therapeutics, Global, Clinical Trials by Phase, 2011 47Table 25: Vitiligo Therapeutics, Global, Clinical Trials by Status of Development, 2011 48Table 26: Vitiligo Therapeutics, Global, Prominent Sponsors, 2011 49Table 27: Vitiligo Therapeutics, Global, Overall Sponsors, 2011 50Table 28: Vitiligo Therapeutics, Global, Top Companies by Phase, 2011 50Table 29: Clinuvel Pharmaceuticals - Vitiligo, Pipeline, 2011 54Table 30: Switch Biotech - Vitiligo, Pipeline, 2011 55Table 31: Dermira - Vitiligo, Pipeline, 2011 55Table 32: Vitiligo Therapeutics, Global, Deals - 2011 57

List of Figures

Figure 1: Graphic Presentation of Vitiligo 8Figure 2: Vitiligo Therapeutics Market, Global, Revenue ($m), 2006-2011 15Figure 3: Vitiligo Therapeutics Market, Global, Forecast ($m), 2011-2019 17Figure 4: Vitiligo Therapeutics Market, The US, Revenue ($m), 2006-2011 18Figure 5: Vitiligo Therapeutics Market, The US, Forecast ($m), 2011-2019 19Figure 6: Vitiligo Therapeutics Market, France, Revenue ($m), 2006-2011 20Figure 7: Vitiligo Therapeutics Market, France, Forecast ($m), 2011-2019 21Figure 8: Vitiligo Therapeutics Market, Germany, Revenue ($m), 2006-2011 22Figure 9: Vitiligo Therapeutics Market, Germany, Forecast ($m), 2011-2019 23Figure 10: Vitiligo Therapeutics Market, Italy, Revenue ($m), 2006-2011 24Figure 11: Vitiligo Therapeutics Market, Italy, Forecast ($m), 2011-2019 25Figure 12: Vitiligo Therapeutics Market, Spain, Revenue ($m), 2006-2011 26Figure 13: Vitiligo Therapeutics Market, Spain, Forecast ($m), 2011-2019 27Figure 14: Vitiligo Therapeutics Market, The UK, Revenue ($m), 2006-2011 28Figure 15: Vitiligo Therapeutics Market, The UK, Forecast ($m), 2011-2019 29Figure 16: Vitiligo Therapeutics Market, Japan, Revenue ($m), 2006-2011 30Figure 17: Vitiligo Therapeutics Market, Japan, Forecast ($m), 2011-2019 31Figure 18: Opportunity and Unmet Need in the Vitiligo Therapeutics Market 33Figure 19: Strategic Competitor Assessment of the Marketed Products in Vitiligo Therapeutics, 2011 36Figure 20: Vitiligo Therapeutics Pipeline by Phase of Clinical Development, 2011 41Figure 21: Vitiligo Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011 42Figure 22: Technology Trends Analytics Framework, 2011 43Figure 23: Technology Trends Analytics Framework - Description, 2011 44Figure 24: Vitiligo Therapeutics, Global, Clinical Trials by Country, 2011 46Figure 25: Vitiligo Therapeutics, Global, Clinical Trials by Phase (%), 2011 47Figure 26: Vitiligo Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 48Figure 27: Vitiligo Therapeutics, Global, Prominent Sponsors (%), 2011 49Figure 28: Vitiligo Therapeutics, Global, Overall Sponsors (%), 2011 50Figure 29: Vitiligo Therapeutics Market, Drivers and Restraints, 2011 51Figure 30: Implications for Future Market Competition in the Vitiligo Therapeutics Market, 2011 52Figure 31: Vitiligo Therapeutics Market, Global, Future Players, 2011 53Figure 32: GlobalData Market Forecasting Model 61

Companies mentioned

Clinuvel PharmaceuticalsSwitch BiotechDermira

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker